BSLN.SW SIX
Basilea Pharmaceutica AG
1W: -2.8%
1M: +1.8%
3M: +24.6%
YTD: +14.2%
1Y: +43.0%
3Y: +41.7%
5Y: +40.5%
CHF 66.80 ($80.45)
-1.00 (-1.47%)
Weekly Expected Move ±4.6%
CHF 61
CHF 64
CHF 67
CHF 70
CHF 73
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$232M
+11.4% ▲
5Y CAGR: +12.7%
Gross Profit
$193M
+13.7% ▲
5Y CAGR: +13.3%
Operating Income
$52M
-15.7% ▼
Net Income
$40M
-48.2% ▼
EPS (Diluted)
$3.14
-46.1% ▼
EBITDA
$52M
-18.3% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $148M | $148M | $158M | $209M | $232M |
| YoY Growth | +16.1% | -0.2% | +6.7% | +32.3% | +11.4% |
| Cost of Revenue | $24M | $27M | $27M | $39M | $39M |
| Gross Profit | $124M | $121M | $131M | $170M | $193M |
| Gross Margin | 83.7% | 81.9% | 83.0% | 81.5% | 83.1% |
| R&D Expenses | $93M | $74M | $78M | $77M | $106M |
| SG&A Expenses | $30M | $31M | $34M | $32M | $36M |
| Operating Expenses | $123M | $105M | $112M | $109M | $142M |
| Operating Income | $1M | $19M | $19M | $61M | $52M |
| Operating Margin | 0.8% | 12.5% | 12.2% | 29.3% | 22.2% |
| Interest Expense | $8M | $10M | $11M | $4M | $0 |
| Income Before Tax | -$7M | $12M | $10M | $60M | $46M |
| Tax Expense | $37K | -$45K | $10K | -$17M | $6M |
| Net Income | -$7M | $12M | $10M | $78M | $40M |
| Net Margin | -4.6% | 8.2% | 6.6% | 37.2% | 17.3% |
| EPS (Diluted) | $-0.58 | $1.02 | $0.86 | $5.83 | $3.14 |
| EBITDA | $7M | $26M | $23M | $63M | $52M |
| Shares Outstanding | 12M | 12M | 12M | 14M | 13M |